Justin To

Justin To is the current Chief Operating Officer of Gene Therapy at BridgeBio. Justin has held this position for 5 years. Prior to that, they were the Vice President of Business Development and Operations for Gene Therapy at BridgeBio, and before that, the Associate Director of Portfolio Management.

Before joining BridgeBio, Justin To was the Product Commercialization Manager at Flatiron Health for 1 year and 2 months. In this role, they were responsible for leading the design and implementation of a merger management tool across a top 5 PharmaCo to capture >$1B in synergies. Justin also worked with the President and senior leaders of a leading diagnostics company to rearticulate the business strategy for the Board.

Prior to their role at Flatiron Health, Justin To was a Business Analyst at McKinsey & Company for 1 year and 10 months. In this role, they created a valuation model for various launch scenarios for a new neurological drug, a database of drug analogues to predict market penetration of a new drug, and provided project management support for the marketing divisions of two pharmaceutical companies to support the launch of a new psychiatric drug.